Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U. Joerger M, et al. Among authors: fischer jr. Ann Oncol. 2016 Oct;27(10):1895-902. doi: 10.1093/annonc/mdw290. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502710 Free article. Clinical Trial.
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. Schmittel A, et al. Among authors: fischer b, fischer jr, fischer von weikersthal l. Ann Oncol. 2011 Aug;22(8):1798-804. doi: 10.1093/annonc/mdq652. Epub 2011 Jan 25. Ann Oncol. 2011. PMID: 21266516 Free article. Clinical Trial.
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators. Kreuter M, et al. Among authors: fischer jr. Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15. Ann Oncol. 2013. PMID: 23161898 Free article. Clinical Trial.
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA. Soria JC, et al. Among authors: fischer jr. Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628. Ann Oncol. 2017. PMID: 29045535 Free PMC article. Clinical Trial.
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. Planchard D, et al. Among authors: fischer jr. Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20. Ann Oncol. 2020. PMID: 32201234 Free article. Clinical Trial.
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M. Heigener DF, et al. Among authors: fischer jr. Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3. Lung Cancer. 2014. PMID: 24560332 Clinical Trial.
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C. Scagliotti GV, et al. Among authors: fischer jr. J Thorac Oncol. 2012 Jun;7(6):1053-7. doi: 10.1097/JTO.0b013e3182519d79. J Thorac Oncol. 2012. PMID: 22588156 Free article. Clinical Trial.
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.
Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, Schumann C, Serke M, Zaun S, Dietel M, Thomas M. Schuette W, et al. Among authors: fischer jr. Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61. doi: 10.1158/1055-9965.EPI-14-1149. Epub 2015 Jun 12. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 26070531
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Schuler M, et al. Among authors: fischer jr. Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17. Oncologist. 2014. PMID: 25232040 Free PMC article.
280 results